Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

@article{Canon2007InhibitionOR,
  title={Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis},
  author={Jude R. Canon and Martine M. Roudier and Rebecca Bryant and Sean E Morony and Marina Stolina and Paul J. Kostenuik and William C. Dougall},
  journal={Clinical & Experimental Metastasis},
  year={2007},
  volume={25},
  pages={119-129}
}
Bone metastases cause severe skeletal morbidity including fractures and hypercalcemia. Tumor cells in bone induce activation of osteoclasts, which mediate bone resorption and release of growth factors from bone matrix, resulting in a “vicious cycle” of bone breakdown and tumor proliferation. Receptor activator of NF-κB ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival, and is blocked by a soluble decoy receptor, osteoprotegerin (OPG). In human malignancies… CONTINUE READING
85 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 85 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

RANK is expressed in human breast tumors and is functional on breast cancer cells

  • M Roudier, M Chaisson, D Branstetter
  • Breast Cancer
  • 2006
1 Excerpt

Antitumor efficacy of the RANK ligand inhibitor OPG-Fc in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models

  • R Miller, J Jones, M Tometsko
  • J Bone Miner Res
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…